Subscribe to Newsletter
Outside the Lab Point of care testing, COVID-19, Omics, Microbiology and immunology

What’s New in Infectious Disease?

Credit: Novel Coronavirus SARS-CoV-2 by NIAID-RML / CC BY

Each month, we carefully curate the top stories across the field of infectious disease – highlighting the latest news, industry insights, and clinical research. Want to receive these updates directly into your inbox? Sign up here.

Four years on, what’s happening with SARS-CoV-2?

Four years ago we were encapsulated within the COVID-19 pandemic, with many of us under lockdown in our homes and waiting for the day we could reconnect as a society. Today, vaccines are available across the world to keep the spread of the disease at bay, but SARS-CoV-2 continues to fight to keep its head above water.

Last year, I shared a story on the origins of SARS-CoV-2 and how it initially spread to humans. With this information, researchers hoped to have more knowledge in preventing further pandemics, but the evidence seemed to run dry… In September 2023, Madeline Ball shared her views on upcoming infectious disease research in the breath analysis space.

Now, a micro-immunoelectrode biosensor is set to change the game for SARS-CoV-2 and infectious disease detection. In less than a minute, this breath aerosol analyzer can confirm the presence of COVID-19.

What exciting diagnostic technology do you have your eye on? We’d love to hear about it.

In Other News…

Researchers say that use of unboiled tap water for nasal rinsing is linked to fatal amoeba infections from Naegleria fowleri organism. Link

DNA sequencing research of Tasmanian devils reveals genomic interactions with an infectious cancer – devil facial tumor disease. Link

New blood test provides researchers with insights into the immune response to the Epstein Barr Virus (EBV). Link

Researchers note vulnerability for contamination through sinks and other water sources to carbapenemase-producing Enterobacterales (CPE), following a study of the multidrug-resistant bacteria at a pediatric hospital ward. Link

Positive phase III trial results for Pfizer’s Abrysvo in adults aged 18 to 59 at increased risk of RSV disease; Pfizer intends to seek approval in this age group. Link

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Jessica Allerton

Deputy Editor, The Pathologist

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine